Cargando…

Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders

Clonal cytogenetic evolution (CE) (i.e., acquisition of new chromosomal aberrations over time) is relevant for the progression of myelodysplastic syndromes (MDS). We performed detailed analysis of CE in 729 patients with MDS and related disorders. Patients with CE showed shorter survival (median OS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schanz, Julie, Cevik, Naciye, Fonatsch, Christa, Braulke, Friederike, Shirneshan, Katayoon, Bacher, Ulrike, Haase, Detlef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841340/ https://www.ncbi.nlm.nih.gov/pubmed/29515104 http://dx.doi.org/10.1038/s41408-018-0061-z

Ejemplares similares

Rare Cytogenetic Abnormalities in Myelodysplastic Syndromes
por: Bacher, Ulrike, et al.
Publicado: (2015)

Cytogenetic features in myelodysplastic syndromes
por: Haase, Detlef
Publicado: (2008)

Clonal evolution in myelodysplastic syndromes
por: da Silva-Coelho, Pedro, et al.
Publicado: (2017)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes
por: Martin, Roman, et al.
Publicado: (2018)

Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL).
por: Sozzi, G., et al.
Publicado: (1990)

Clonal hematopoiesis with TET2 mutations spawning synchronous primary central nervous system lymphoma and myelodysplastic syndrome
por: Treiber, Hannes, et al.
Publicado: (2023)

Cytogenetic evolution and clonal proliferation in acute transformation of chronic granulocytic leukaemia.
por: Spiers, A. S., et al.
Publicado: (1968)

Cytogenetic and Genetic Abnormalities with Diagnostic Value in Myelodysplastic Syndromes (MDS): Focus on the Pre-Messenger RNA Splicing Process
por: Douet-Guilbert, Nathalie, et al.
Publicado: (2022)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
por: Calvete, Oriol, et al.
Publicado: (2023)

3D Telomere Structure Analysis to Detect Genomic Instability and Cytogenetic Evolution in Myelodysplastic Syndromes
por: Rangel-Pozzo, Aline, et al.
Publicado: (2019)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
por: Valent, Peter, et al.
Publicado: (2010)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

Guiding the global evolution of cytogenetic testing for hematologic malignancies
por: Akkari, Yassmine M.N., et al.
Publicado: (2022)

Deletions in the 17q chromosomal region and their influence on the clonal cytogenetic evolution of recurrent meningiomas
por: Hemmer, Sina, et al.
Publicado: (2019)

History and evolution of cytogenetics
por: Ferguson-Smith, Malcolm A
Publicado: (2015)

Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion
por: Feurstein, Simone, et al.
Publicado: (2018)

Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype
por: Mallo, Mar, et al.
Publicado: (2023)

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)
por: Xie, Xiaoqing, et al.
Publicado: (2021)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
por: Lucero, Josephine, et al.
Publicado: (2023)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview
por: Zahid, Mohammad Faizan, et al.
Publicado: (2017)

Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
por: Yan, Yuting, et al.
Publicado: (2022)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
por: Blum, Sabine, et al.
Publicado: (2021)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
por: Hoff, Fieke W., et al.
Publicado: (2023)

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia
por: Malcikova, J, et al.
Publicado: (2015)

Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform
por: Valent, P, et al.
Publicado: (2008)

Comprehensive analysis of mutations and clonal evolution patterns in a cohort of patients with cytogenetically normal acute myeloid leukemia
por: Mat Yusoff, Yuslina, et al.
Publicado: (2021)

Evolution of clonal hematopoiesis
por: van Zeventer, Isabelle A., et al.
Publicado: (2023)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

Computer aided analysis of additional chromosome aberrations in Philadelphia chromosome positive acute lymphoblastic leukaemia using a simplified computer readable cytogenetic notation
por: Bradtke, Jutta, et al.
Publicado: (2003)

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
por: Platzbecker, Uwe, et al.
Publicado: (2022)

Multi Cytogenetic Changes in a Patient as Co-Existing MDS and CLL Progresses
por: Li, Xiangxin, et al.
Publicado: (2021)

What Clonal Hematopoiesis Can Teach Us About MDS
por: Chan, Irenaeus C. C., et al.
Publicado: (2022)

Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS
por: Buck, Michèle C., et al.
Publicado: (2023)

Cytogenetic features in primary myelodysplastic syndrome Egyptian patients
por: Elnahass, Yasser, et al.
Publicado: (2018)

Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study
por: Wesa, Kathleen M., et al.
Publicado: (2014)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
por: de Witte, Theo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u416vunkr8kui0fl3jr133qj3v